We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2001
Security National Financial
SNFCA
$229M
| $1.42K | ﹤0.01% |
+194
| New | +$1.24K |
|
2002
Forestar Group
FOR
$1.37B
| $1.38K | ﹤0.01% |
61
-5,025
| -99% | -$96.7K |
|
2003
Valhi
VHI
$508M
| $1.34K | ﹤0.01% |
104
-3,007
| -97% | -$43.9K |
|
|
GAN
2004
DELISTED
GAN Ltd
GAN
| $1.32K | ﹤0.01% |
808
-4,889
| -86% | -$6.96K |
|
2005
Neurogene
NGNE
$678M
| $1.29K | ﹤0.01% |
78
-17
| -18% | -$279 |
|
2006
Tenable Holdings
TENB
$4.24B
| $1.26K | ﹤0.01% |
29
-24
| -45% | -$981 |
|
2007
Vodafone
VOD
$40.8B
| $1.26K | ﹤0.01% |
133
-3,039
| -96% | -$31.9K |
|
|
EMKR
2008
DELISTED
Emcore Corp
EMKR
| $1.25K | ﹤0.01% |
166
-46
| -22% | -$417 |
|
2009
Core Molding Technologies
CMT
$206M
| $1.23K | ﹤0.01% |
+54
| New | +$1.05K |
|
2010
Lyft
LYFT
$5.98B
| $1.22K | ﹤0.01% |
127
-619,185
| -100% | -$5.95M |
|
2011
Avista
AVA
$3.05B
| $1.22K | ﹤0.01% |
31
-5
| -14% | -$212 |
|
2012
Immuneering
IMRX
$285M
| $1.15K | ﹤0.01% |
+113
| New | +$1.09K |
|
|
MAPS
2013
DELISTED
WM TECHNOLOGY INC A
MAPS
| $1.13K | ﹤0.01% |
+1,354
| New | +$1.11K |
|
|
MACK
2014
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $1.11K | ﹤0.01% |
90
| – | – |
|
2015
C4 Therapeutics
CCCC
$421M
| $1.11K | ﹤0.01% |
402
-3,055
| -88% | -$9.82K |
|
2016
Tenaya Therapeutics
TNYA
$150M
| $974 | ﹤0.01% |
+166
| New | +$965 |
|
|
KE
2017
Kimball Electronics
KE
$576M
| $967 | ﹤0.01% |
35
+9
| +35% | +$213 |
|
|
FXLV
2018
DELISTED
F45 Training Holdings Inc.
FXLV
| $930 | ﹤0.01% |
1,860
+573
| +45% | +$488 |
|
2019
Aterian
ATER
$11.9M
| $885 | ﹤0.01% |
+160
| New | +$1.25K |
|
2020
Curis
CRIS
$2.74M
| $864 | ﹤0.01% |
3
-19
| -86% | -$6.18K |
|
2021
Allogene Therapeutics
ALLO
$601M
| $845 | ﹤0.01% |
170
| – | – |
|
2022
Eos Energy Enterprises
EOSE
$1.5B
| $833 | ﹤0.01% |
+192
| New | +$504 |
|
|
IRD
2023
Opus Genetics
IRD
$488M
| $833 | ﹤0.01% |
+192
| New | +$912 |
|
|
TALK
2024
DELISTED
Talkspace
TALK
| $814 | ﹤0.01% |
641
| – | – |
|
|
HARP
2025
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $804 | ﹤0.01% |
113
-172
| -60% | -$1.19K |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.